A carregar...
Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogs
The melanocortin‐4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 administered subcutaneously to healthy dogs. Dogs were treated with high‐ (2.25 mg kg(−1)) (n = 5) and low‐...
Na minha lista:
| Publicado no: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8135083/ https://ncbi.nlm.nih.gov/pubmed/34014033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.777 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|